NAPROXEN Axicur 250 mg tablets, 30 pcs

Instructions for use for NAPROXEN Axicur 250 mg tablets, 30 pcs

Detailed instructions for NAPROXEN Axicur 250 mg tablets, 30 pcs

Field of use

• Naproxen is the active ingredient of the drug.
• Naproxen is an anti -inflammatory and fever -lowering active ingredient, which is used in the case of regulation pain and abdominal cramps.

Mode of action

Naproxen axicur 250 mg tablets (pack size: 30 pcs) acts pain relieving for menstrual pain and its accompanying symptoms.

Active ingredients / ingredients / ingredients

Ingredients of Naproxen axicur 250 mg tablets (pack size: 30 pc):

1 tablet contains 250 mg naproxen.

The other components are: lactose monohydrate, corn starch, iron (III) oxide, hyprolose, crospovidone, magnesium stearate.

Contradictions

In the case of known hypersensitivity to one of the ingredients mentioned above, the product should not be used.

dosage

Recommendation from Naproxen axicur 250 mg tablets (pack size: 30 pc):

Always take this medicine exactly as described in this package insert or follow the consultation made with your doctor or pharmacist.

The recommended dose for adults and adolescents from the age of 12 is:

First dose: 1 tablet (corresponding to 250 mg naproxen)
To take further single dose at a distance of 8–12 hours: 1 tablet (corresponding to 250 mg naproxen)
Maximum daily dose: up to 3 tablets (corresponding to 750 mg naproxen)

Patients with limited liver or kidney function should not take more than 2 tablets a day, spread over 2 individual doses.

Please take the tablet unscrewed with plenty of liquid (e.g. a glass of water) before eating. This promotes the occurrence of action.

For patients who have a sensitive stomach, it is advisable to take NaProxen Axicur 250 mg tablets during meals.

Please speak to your doctor or pharmacist if you have the impression that the effect of Naproxen Axicur 250 mg tablets is too strong or too weak.

Taking

• Please take the tablet unscrewed with plenty of liquid (e.g. a glass of water) before eating. This promotes the occurrence of action.
• For patients who have a sensitive stomach, it is advisable to take the tablets during meals.

Patient information

• Warnings and Precautions
  • Please speak to your doctor or pharmacist before taking Naproxen.
  • Side effects can be reduced by using the lowest effective dose via the shortest period required for symptom control.
  • Security in the gastrointestinal tract
    • A simultaneous use of NSAR, including so-called COX-2 inhibitors (cyclooxigenase-2-inhibitors), should be avoided.
  • Older patients
    • Side effects occur more frequently in older patients after using NSAR, in particular bleeding and breakthroughs in the stomach and intestinal area, which may be fatal. Therefore, particularly careful medical monitoring is required in older patients.
  • Bleeding of the gastrointestinal tract, ulcers and breakthroughs (perforations)
    • Bleeding of the gastrointestinal tract, ulcers and perforations, also with a fatal outcome, were reported during treatment with all NSAIDs. They occurred with or without prior warning symptoms or serious events in the gastrointestinal tract in the prehistory at any time of therapy.
    • The risk of the occurrence of gastrointestinal bleeding, ulcers and breakthroughs is higher with increasing NSAR dose, in patients with ulcers in the history, especially with the complications bleeding or breakthrough and in older patients. These patients should begin treatment with the lowest available dose.
    • For these patients and for patients who accompanying therapy with low-dosed acetylsalicylic acid (ASA) or other medicines that can increase the risk of gastrointestinal diseases, combination therapy with gastric mucosal-protecting medicines should be (e.g. Misoprostol or proton pump inhibitor).
    • If you have a history of side effects on the gastrointestinal tract, especially at older age, you should report any unusual symptoms in the abdomen (especially gastrointestinal bleeding), especially at the beginning of the therapy.
    • Caution is advisable if you get medicines that can increase the risk of ulcers or bleeding, such as: B. oral corticosteroids, anti-blood clotting drugs such as warfarin, selective serotonin reuptake inhibitors that are used, among other things, to treat depressive moods, or thrombocyte aggregation inhibitors such as ASA (see category "Interactions").
    • If you have gastrointestinal bleeding or ulcers during treatment during treatment, the treatment is to be stopped.
    • In patients with a gastrointestinal disease in the prehistory (Ulzerosa colitis, Crohn's disease), caution should be used because their condition can deteriorate (see categoia "Side effects").
  • Effects on the cardiovascular system
    • Medicines such as this preparation may be associated with a slightly increased risk of heart attacks ("heart attack") or strokes. Any risk is more likely with high doses and longer treatment. Do not exceed the recommended dose or duration of treatment (maximum 4 days)!
    • If you have heart problems or a previous stroke or think that you could have a risk for these diseases (e.g. if you have high blood pressure, diabetes or high cholesterol or smokers), you should discuss your treatment with your doctor or pharmacist.
  • Skin reactions
    • Under NSAR therapy, serious skin reactions with redness and bladder formation, some with a fatal outcome, were reported (exfediative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis/lyell syndrome; see category "side effects"). The highest risk of such reactions seems to exist at the beginning of therapy, since these reactions occurred in the majority of cases in the first month of treatment. At the first sign of rashes, mucosal defects or other signs of a hypersensitivity reaction, the tablets should be stopped and the doctor should be consulted immediately.
  • Other information
    • Naproxen should only be used with the strict weighing of the benefit-risk ratio:
      • for certain innate blood formation disorders (e.g. acute intermittent porphyria);
      • for certain autoimmune diseases (systemic lupus erythematosus and mixed collagenosis).
    • A particularly careful medical monitoring is required:
      • with limited kidney or liver function;
      • directly after larger surgical interventions;
      • in allergies (e.g. skin reactions to other medicines, asthma, hay fever), chronic nasal mucosal swelling or chronic, the breathingeGE narrowing respiratory diseases.
    • Severe acute hypersensitivity reactions (for example anaphylactic shock) are very rarely observed. At the first sign of a severe hypersensitivity reaction after taking NAPROXEN, the therapy must be canceled. The symptoms corresponding, medically required measures must be initiated by expert persons.
    • Naproxen can temporarily inhibit the platelet function (thrombocyte aggregation). Patients with blood clotting disorders should therefore be carefully monitored.
    • With long -term administration of naproxen, regular control of the liver values, the kidney function and the blood count is required.
    • When taking Naproxen before surgery, the doctor or dentist must be asked or informed.
    • The longer use of all kinds of painkillers against headaches can make them worse. If this is the case or if this is suspected, medical advice should be obtained and treatment can be broken off. The diagnosis of headache in the case of medication must be suspected in patients who suffer from frequent or daily headaches, although (or precisely because) they regularly take medicines for headaches.
    • In general, the habitual intake of pain relievers, especially when combining several pain relieving active ingredients, can lead to permanent kidney damage with the risk of kidney failure (analgesic nephropathy).
    • NSAR can mask symptoms of infection or fever.
    • Interaction with laboratory tests: NAPROXEN can interfere with certain tests of 5-hydroxyindolic acid in the urine.
  • Children
    • Please note the information under category "contraindication".

• Wateriness and ability to operate machines
  • Since, when using naproxen in higher doses, central nervous side effects such as tiredness and dizziness can occur, the reaction capacity can be changed in individual cases and the ability to actively participate in road traffic and to operate machines can be impaired. This applies even more in combination with alcohol. You can then no longer react quickly and specifically to unexpected and sudden events. Do not drive a car or other vehicles in this case! Do not operate any tools or machines! Do not work without a safe grip!

Pregnancy

• If you are pregnant or breastfeed, or if you suspect that you are pregnant or intend to become pregnant, ask your doctor or pharmacist for advice before taking this drug.
• Pregnancy
  • If pregnancy is determined during the application of naproxen, the doctor must be notified. You can only use Naproxen in the first and second thirds of pregnancy after consultation with your doctor. In the last third of pregnancy, the tablets must not be used due to an increased risk of complications for mother and child.
• Breastfeeding
  • The active ingredient naproxen and its dismantling products pass into breast milk in small quantities. As a precaution, an application of naproxen during breastfeeding should be avoided.
• Reproductive ability
  • This medicine belongs to a group of drugs (NSAID) that can affect the fertility of women. This effect is reversible after stopping the drug.

Hints

Naproxen axicur 250 mg tablets (pack size: 30 pcs) Areas of application: pain relieving, fever-lowering and anti-inflammatory drug (non-steroidal anti-rheumatics/anti-phlogistics, NSAR). Is used for brief symptomatic treatment of light to moderately severe pain, such as menstrual pain, headache, toothache and fever.
Contains lactose. Note leaflet.
Do not apply longer for pain or fever without medical advice than specified in the package insert. Read the package supplement and ask your doctor or pharmacist for risks and side effects.
axicorp Pharma GmbH, 61381 Friedrichsdorf. As of November 2020